Apollomics (APLM) Intangibles (2021 - 2025)
Apollomics' (APLM) quarterly Intangibles came in at $228000.0 in Q2 2025, down 95.2% year-over-year from $4.7 million in Q2 2024, and down 86.87% quarter-over-quarter from $1.7 million in Q4 2024.
Analysis
Apollomics (APLM) Intangibles (2021 - 2025) Analysis & Trends
Apollomics (APLM) has reported Intangibles for 5 consecutive years, with $228000.0 the latest figure, recorded in Q2 2025.
- On a quarterly basis, Intangibles fell 95.2% year-over-year to $228000.0 in Q2 2025; TTM through Jun 2025 was $228000.0, a 95.2% decrease from a year earlier, with the FY2024 full-year figure at $1.7 million, down 88.23% from the prior year.
- Intangibles was $228000.0 for Q2 2025 at Apollomics, down from $1.7 million in the prior quarter.
- Over five years, Intangibles peaked at $14.8 million in Q4 2021 and troughed at $228000.0 in Q2 2025.
- A 5-year average of $9.4 million and a median of $14.8 million in 2023 frame the typical range for Intangibles.
- Across the five-year window, Intangibles decreased 0.14% in 2022 and slumped 95.2% in 2025, its largest moves.
- Over 5 years, Intangibles stood at $14.8 million in 2021, then declined by 0.14% to $14.8 million in 2022, then declined by 0.14% to $14.8 million in 2023, then plunged by 88.23% to $1.7 million in 2024, then plunged by 86.87% to $228000.0 in 2025.
- The last three Intangibles figures came in at $228000.0 (Q2 2025), $1.7 million (Q4 2024), and $4.7 million (Q2 2024), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 20.49 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 14.03 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 412.80 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 1.31 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 266.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 13.52 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | Apollomics | 34.50 Mn | 31.23 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 228,000.00 |
| Dec 31, 2024 | 1.74 Mn |
| Jun 30, 2024 | 4.75 Mn |
| Dec 31, 2023 | 14.76 Mn |
| Jun 30, 2023 | 14.77 Mn |
| Dec 31, 2022 | 14.78 Mn |
| Dec 31, 2021 | 14.80 Mn |